---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-21-014445"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2021-11-04T23:59:59+00:00"
generated_at: "2026-06-28T12:28:53.634904+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics Q3 net loss $85.6M; UKONIQ revenue $2.0M; ublituximab BLA for RMS submitted

## Summary
- Net loss $85.6M Q3, $254.8M nine months; ex-stock comp net loss $71.6M and $207.8M.
- Product revenue $2.0M Q3, $4.3M YTD from UKONIQ launch (approx 7 months post-approval).
- BLA for ublituximab submitted for RMS; PDUFA date for U2 in CLL set for March 25, 2022.
- Cash $381.4M as of Sept 30; expected to fund operations into 2023.
- R&D $52.0M and SG&A $34.9M in Q3; costs increased due to regulatory submissions and launch.

## SEC filing metadata
- accession: 0001558370-21-014445
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2021-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000155837021014445/0001558370-21-014445-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000155837021014445/tgtx-20211104x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-21-014445
- JSON: https://secwatch.observer/filing/0001558370-21-014445.json
- Plain text: https://secwatch.observer/filing/0001558370-21-014445.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.